EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair

Biochem Pharmacol. 2024 Aug:226:116366. doi: 10.1016/j.bcp.2024.116366. Epub 2024 Jun 13.

Abstract

Previous studies have demonstrated that Eyes Absent 4 (EYA4) influences the proliferation and migration of tumor cells. Notably, studies have established that EYA4 can also limit tumor sensitivity to chemotherapeutic agents. The objective of this study was to investigate the effect of EYA4 in conferring drug resistance in osteosarcoma (OS). Bioinformatics, histological, and cellular analyses revealed that the expression level of EYA4 was higher in OS tissues than in healthy tissues/cells and in resistant tissues/cells compared with sensitive tissues/cells. In vitro and in vivo experiments demonstrated that EYA4 knockdown increased the sensitivity of OS to doxorubicin (DOX). Conversely, overexpression of EYA4 decreased the sensitivity of OS to DOX. Exploration of the resistance mechanism exposed that EYA4 facilitates DNA double-strand break (DSB) repair, a typical mode of DNA damage repair (DDR). Subsequently, our findings indicated that EYA4 could directly interact with histone H2AX to activate the DDR pathway. Taken together, our observations indicated that EYA4 may serve as a target molecule for reversing drug resistance in OS patients.

Keywords: Chemoresistance; DNA damage repair; Doxorubicin; EYA4; Osteosarcoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic* / pharmacology
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / genetics
  • Bone Neoplasms* / metabolism
  • Bone Neoplasms* / pathology
  • Cell Line, Tumor
  • DNA Damage* / drug effects
  • DNA Repair* / drug effects
  • DNA Repair* / physiology
  • Doxorubicin* / pharmacology
  • Drug Resistance, Neoplasm* / drug effects
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude*
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / genetics
  • Osteosarcoma* / metabolism
  • Osteosarcoma* / pathology
  • Trans-Activators / genetics
  • Trans-Activators / metabolism
  • Xenograft Model Antitumor Assays / methods

Substances

  • Doxorubicin
  • EYA4 protein, human
  • Antibiotics, Antineoplastic
  • Trans-Activators